1. Home
  2. COAG vs IMKTA Comparison

COAG vs IMKTA Comparison

Compare COAG & IMKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

COAG

Hemab Therapeutics Holdings Inc. Common Stock

SELL

Current Price

$30.17

Market Cap

1.9B

Sector

Health Care

ML Signal

SELL

Logo Ingles Markets Incorporated

IMKTA

Ingles Markets Incorporated

SELL

Current Price

$86.14

Market Cap

1.6B

ML Signal

SELL

Company Overview

Basic Information
Metric
COAG
IMKTA
Founded
2020
1963
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Food Chains
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
2026
1994

Fundamental Metrics

Financial Performance
Metric
COAG
IMKTA
Price
$30.17
$86.14
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $62.67
N/A
AVG Volume (30 Days)
★ 515.7K
92.7K
Earning Date
11-05-2026
11-25-2026
Dividend Yield
N/A
★ 0.76%
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $5,334,032,609.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$15.91
Revenue Growth
★ N/A
N/A
52 Week Low
$27.38
$67.17
52 Week High
$55.42
$95.62

Technical Indicators

Market Signals
Indicator
COAG
IMKTA
Relative Strength Index (RSI) 37.40 56.74
Support Level $28.46 $82.95
Resistance Level $33.93 $89.53
Average True Range (ATR) 2.32 1.89
MACD 0.43 0.15
Stochastic Oscillator 43.46 46.84

Price Performance

Historical Comparison
COAG
IMKTA

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

About IMKTA Ingles Markets Incorporated

Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.

Share on Social Networks: